Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Public offering nets $325mm for Clovis Oncology

Executive Summary

Clovis Oncology Inc. netted $325mm through an upsized public offering of 3.9mm common shares (including the overallotment) at $88. (The company originally intended to raise $250mm from the sale.) Some of the proceeds will support marketing expenses for Rubraca (rucaparib) for ovarian cancer in the US (and in the EU, once approved there). Funds will also go towards ongoing development activities and potential in-licensing or acquisition of additional cancer projects.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register